|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, Vol. 91 No. 5 (March 1), 1998:
pp. 1479-1495
REVIEW ARTICLE
By
From the Oregon Cancer Center at Oregon Health Sciences University;
the Portland VA Medical Center; and the Departments of Medicine,
Molecular Microbiology and Immunology at Oregon Health Sciences
University, Portland.
THROMBOCYTOPENIA, anemia,
lymphocytopenia, monocytopenia, and neutropenia and permutations of
these abnormalities are found in most patients with acquired
immunodeficiency syndrome (AIDS). In virtually all patients with
advanced AIDS (group IV), pancytopenia is the rule. More than 90% of
such patients are anemic and an equal fraction have either neutropenia
or monocytopenia.1 Although immune thrombocytopenia is a
common cause of low platelet counts in human immunodeficiency virus
(HIV)-infected patients, the majority of other types of cytopenias
usually reflect bone marrow (BM) dysfunction. Even so, the causes of
these cytopenias are clearly heterogeneous and can, in a large number
of cases, be attributed to the widely recognized hematopoietic
suppressive effects of certain types of intercurrent infections (eg,
cytomegalovirus, parvovirus, hepatitis virus, and mycobacterial
infection), or of drugs commonly used in AIDS patients (zidovudine,
gancyclovir, trimethoprim/sulfa). The multiple causes of
marrow failure in patients with AIDS1-3 account for the
mixed histological findings on BM examinations of these
patients.1 BM biopsy samples and aspirates are most often
nonspecifically abnormal. To be sure, certain findings are more than
nonspecific. The discovery of abundant megakaryocytes in the BM of a
patient with isolated thrombocytopenia, for example, is highly
suggestive of idiopathic thrombocytopenic purpura (ITP). Erythroid
hypoplasia suggests either parvovirus infection (a rare cause of anemia
in patients with HIV infection4) or infection of the marrow
with mycobacterium avium complex.1 Interestingly, frank
hypocellularity is the exception and aplasia is rare. Taking these
diagnostic complexities into account, it has been impossible, from
examination of clinical material alone, to determine whether HIV-1
itself has any direct impact on hematopoietic activity.
We seek in this review not to catalogue the spectrum of hematopoietic
defects that occur in patients with AIDS, but to focus specifically on
the influence HIV-1 itself imposes on hematopoietic cells. For more
than a decade, research teams worldwide have sought to identify a
causal role for HIV-1 and its gene products in the hematopoietic
defects that develop in patients with AIDS and more clear paradigms
have emerged. The most important of these is that the greatest impact
of viral infection on growth and differentiation of hematopoietic
progenitor cells results from the capacity of the virus to infect and
perturb the hematopoietic regulatory function of auxiliary cells, not
from its capacity to infect progenitors and stem cells themselves. Here
we review the evidence in support of this model. We will focus on two
commonly encountered AIDS-related hematopoietic abnormalities in
clinical practice, regenerative marrow failure and lymphoid neoplasms.
Because BM failure and lymphomas are common consequences of AIDS
progression, and limit both survival and quality of life, a clear
pathophysiological picture of these disorders and the molecular
mechanism(s) by which HIV-1 causes or sets the stage for them, is an
essential prerequisite for the development of rational strategies for
therapy and prevention.
Recovery from myelosuppression induced by treatment with antivirals and
with antilymphoma regimens is consistently more toxic to hematopoietic
tissues of AIDS patients than in those of non-AIDS patients. Although
many AIDS patients have BM failure before therapy,5-12 a
greater number experience inordinate myelosuppressive toxicity after
conventional antilymphoma13 or antiviral14
chemotherapy unless hematopoietic growth factors are
used.14-16 Even when growth factors are used, conventional
therapy is extremely toxic. Levine et al17 recently
described the results of their study using ABVD (Adriamycin [Pharmacia
& Upjohn, Kalamazoo, MI], bleomycin, Velban [Lilly, Indianapolis,
IN], and Dacarbazine [Bayer, West Haven, CT]) with
granulocyte colony-stimulating factor (G-CSF) support of 21 HIV+ patients with Hodgkin's disease, in which nearly
every patient had either severe and prolonged thrombocytopenia
and/or neutropenia.17 Theoretically, causes of
regenerative failure might reflect dysfunction of the hematopoietic
progenitor cell population, dysfunction of cells that control the
regenerative response by releasing hematopoietic growth factors, or
activation of gene programs that serve to inhibit one or both of these
two cell types.18 The weight of evidence today quite
clearly suggests that the progenitor populations are intact and largely
uninfected, but that auxiliary cells are very consistently infected and
broadly dysfunctional.
Infection of Hematopoietic Progenitor Cells Is Infrequent and not
Substantially Involved in the Pathogenesis of Marrow Failure
Infected Auxiliary Cells and Regenerative Failure
T cells.
The release of hematopoietic growth factors by T cells is variably
influenced by HIV-1 infection. Although IL-6 production is
increased,34 production of IL-2 is reduced by
HIV-135 possibly via the effects of HIV-1
nef,36 which is known to bind protein kinase C Monocyte/macrophages.
HIV-1 tat and gp120 induce cytokine expression in monocytes, but
whether HIV-1 infection of monocytes achieves the same level of
induction is arguable. Molina et al41 report that
peripheral blood mononuclear cells (PBMC) infected with myriad strains
of HIV-1 do not express IL-1, IL-6, or tumor necrosis factor- Microvascular endothelial cells (MVEC).
MVEC from a variety of organs including the brain,48,49
liver,50 kidney,51 and BM3,19 are
permissive for HIV-1 infection. Of greater relevance to the issue of
regenerative marrow failure, BM MVEC cells are always found to be
infected by HIV-1 in seropositive patients regardless of the stage of
their disease.19 Moreover, while constitutive production of
hematopoietic growth factors by such cells (either alone or admixed
with other BM stromal cell types) is normal, IL-1 induced production of
G-CSF and IL-6 is significantly reduced.19 This suggests
that HIV-1 infection of BM MVEC reduces the capacity of hematopoietic
stroma to respond to regulatory signals that normally augment blood
cell production during periods of increased demand. The dysfunction in
marrow stroma does not seem to derive simply from direct interdiction
of IL-1 responses in MVEC because pure populations of MVEC, at least
from brain, do not respond abnormally to IL-1 after infection (Moses et
al, unpublished, April 1997). Therefore, it is likely that
the MVEC infection induces release of factors that influence the
behavior of other IL-1-responsive cells in the stroma, most of which
are not infected (Fig 1). The mechanisms by
which this occurs are currently under investigation in our
laboratories. The recent report of hematopoietic support dysfunction of
HIV-1-infected mixed BM stromal cell cultures containing only 2%
MVEC52 supports the notion that collaboration between infected and uninfected cells results in the failure of the stroma to
support myeloid hematopoiesis.
Uninfected (bystander) Auxiliary Cells and Regenerative Marrow
Failure
T cells.
The clonal suppressive effect of CD8+ hematopoietic
inhibitory T cells (HIT cells) has been recognized for
decades.53,54 Such cells have been discovered in
HIV-1-infected patients.55 Specifically, clonal growth of
CFU-GEMM, BFU-E, and CFU-GM from marrows of HIV-1+ patients
significantly increased after depletion of CD8+,
Monocyte/macrophages.
Apoptosis of lymphoid cells in nodal tissues of patients with HIV-1
infection occurs in cells that are not themselves infected by HIV-1.
Priming of the Fas pathway has also been shown in lymphocytes from
HIV-1-infected individuals, but cells undergoing apoptosis can be
virus free. Badley et al56 have found that HIV-1 induces Fas ligand (FasL) expression in infected monocytes and that this effect
may account, indirectly, for apoptotic signals to both lymphocytes and,
in our view, possibly progenitor cells (Fig 2). In this report, the
investigators argue that this bystander effect, in which HIV-1 induces
both Fas and FasL, is a mechanism that can account for lymphocyte
depletion during the course of HIV-1 disease. Hematopoietic progenitor
cells are also quite susceptible to Fas-induced apoptosis and this
particular apoptotic pathway likely accounts for a variety of BM
failure states (Fig
2).57-59Therefore, it is likely that FasL induction in auxiliary cells may
be of substantial relevance, particularly if the Fas pathway is primed
by IFN-
BM stromal cells.
Zauli et al33 evaluated the effect of a short-term exposure
(2 hours) to two different lymphocytotropic strains of HIV-1 (HIVIIIB
and ICR-3) on the survival of a factor-dependent CD34+
hematopoietic cell line (TF-1). Although HIV-1-treated TF-1 cells underwent programmed cell death, the response was reversible with optimal doses of IL-3 or GM-CSF or both. Moreover, this group found no
signs of productive or latent infection of these cells but did notice
that treatment of TF-1 cells with recombinant gp120 plus a polyclonal
anti-gp120 antibody, or with anti-CD4 monoclonal antibody (MoAb) plus
rabbit anti-mouse IgG, significantly increased the percentage of cells
undergoing apoptosis. They reasoned that the apoptotic response was the
result of an interaction of gp120 with the CD4 receptor, which was
expressed at a low level on the surface of TF-1 cells.
Blunted Inductive Responses in Other Auxiliary Cells
AIDS patients are at increased risk for developing clinically
aggressive B-cell non-Hodgkin's lymphomas (NHL).63-66
Unlike other AIDS-associated malignancies, the AIDS-associated NHL
(AIDS-NHL) develop in every population group at risk for AIDS. Current
estimates indicate that 5% to 10% of HIV-1-infected patients develop
this life-threatening disease. The etiology of AIDS-NHL is unknown and
is likely to be complex. With some interesting
exceptions,67,68 the malignant B cells in AIDS-NHL are not
directly infected by HIV-1,69-72 suggesting that HIV-1
contributes to B-cell neoplasia via indirect mechanisms. Given the high
degree of molecular heterogeneity seen within this group of neoplasms,
it is likely that multiple pathways operate individually or in concert
within the context of HIV-1 infection to promote lymphomagenesis.
Distinctive Features of AIDS-NHL
Clinical behavior.
Biggar et al74 recently linked AIDS and cancer registry
data for the 1980-1990 decade to evaluate the overall lymphoma risk for
persons with AIDS and determined a risk of 348-fold for high-grade lymphomas but only 14-fold for low-grade lymphomas. In another study,
over 80% of AIDS-NHL were classified as high-grade tumors while less
than 40% of non-AIDS NHL qualified as high-grade
neoplasms.75 The aggressive clinical behavior of the
AIDS-NHL has necessitated the creation of a separate classification
system. Histologically, the majority of systemic AIDS-NHL fall into one
of three main categories: (1) high-grade, small noncleaved cell
(Burkitt's and Burkitt's-like) lymphomas (SNCCL), (2) high-grade,
large cell immunoblastic lymphomas (IBL), and (3) intermediate grade,
large noncleaved cell lymphomas (LNCCL). Because of their aggressive clinical behavior, the LNCCL have been functionally classified along
with the high-grade IBL as diffuse large cell lymphomas (DLCL). A
subtype of "intermediate" lymphomas exhibiting features of both
SNCCL and immunoblastic DLCL has also been described.76 The
recently described CD30+ anaplastic
lymphomas,77 body-cavity-based or primary effusion lymphomas (BCBL/PEL),78,79 and plasmablastic lymphomas
(PBL) of the oral cavity80 have also been included in this
category, although recent opinion suggests the reclassification of the
PEL and PBL, as well as the "intermediate" NHL, as separate
pathologic entities.81 Collectively, DLCL comprise about
two thirds of the systemic NHL while SNCCL make up approximately one
third. T cell, non-T/non-B cell, and low-grade NHL comprise the
remainder. The primary central nervous system lymphomas (PCNSL), which
account for approximately 20% of all AIDS-NHL, fall almost exclusively into the high-grade immunoblastic subtype of DLCL.
Extranodal involvement.
The extent of extranodal involvement is a characteristic feature of
AIDS-NHL. Malignant cells arising in the lymph node may seed to
extranodal sites, or the tumor may be exclusively extranodal with no
overt involvement of the lymph nodes.82 The most common sites for extranodal involvement include the gastrointestinal tract,
liver, BM, and meninges for systemic NHL and perivascular cuffing
within the brain parenchyma for the primary CNS NHL.63,83 As the name suggests, PEL do not seed from solid tumors but present exclusively in the body cavities as extranodal lymphomatous effusions.
Association with EBV.
While posttransplant NHL arising in immunocompromised patients are
invariably EBV-associated, only about half of the AIDS-associated systemic NHL are EBV+.69,70,84-86 Approximately
30% of SNCCL are EBV+ and the transforming antigens EBNA-2
and LMP-1 are not expressed.87 The incidence of EBV among
the large cell lymphomas is about 60% to 70%; almost 100% for the
immunoblastic subtype where EBNA-2 and LMP-1 are expressed and a lower
incidence amongst the LNCCL, which have a latency pattern resembling
that of the SNCCL.87 The primary CNS lymphomas are almost
exclusively EBV-infected with a latency pattern characterized by
expression of EBNA-2 and LMP-1.88 EBV-driven
lymphoproliferation in the setting of immunodeficiency is likely to
play a central role in the development of EBV+ AIDS-NHL, as
it does for posttransplant lymphomas. However, the high frequency of
EBV Genetic diversity.
Genetic lesions characteristic of AIDS-NHL are heterogeneous and tend
to segregate with certain histologic subtypes. For example, the
c-myc gene rearrangement is found in almost all SNCCL, but occurs in only one quarter of DLCL and is absent in the primary CNS
lymphomas.89 Inactivation of the tumor suppressor gene p53 occurs in up to 60% of SNCCL but is seen in only a fraction of DLCL,89 while rearrangements of the bcl-6 gene are seen
almost exclusively in DLCL.90 The PEL are generally lacking
any of these genetic lesions but are exclusively and consistently
infected with HHV-8.78,79 The lack of universality of EBV
association and the different patterns of EBV gene expression
contribute further to the genetic diversity of the AIDS-NHL.
Host Factors Contributing to the Development of AIDS-NHL
Chronic immune stimulation.
Primary HIV-1 infection is frequently associated with a persistent and
generalized lymphadenopathy (PGL), characterized by expansion of lymph
node germinal centers in response to the recruitment, proliferation,
differentiation, and apoptotic death of antigen-reactive B
cells.92 HIV-1 itself, as well as other environmental or
self antigens, may contribute to this polyclonal B-cell hyperplasia and
hypergammaglobulinemia. Antigen-driven B-cell hyperproliferation would
not only increase the risk for genetic accidents and the emergence of
transformed B-cell clones, but would contribute to the expansion of
such neoplastic clones. In support of a role for chronic antigen
stimulation in the development of AIDS-NHL, Riboldi et al93
showed that Burkitt's lymphomas derived from AIDS patients produced
self-reactive IgM antibodies, and that somatic mutations within the IgM
VH segment were reminiscent of those seen in Ig genes from
other autoreactive B-cell clones.
Cytokines.
A characteristic feature of AIDS is the existence of a deregulated
cytokine network.92 Some of the key cytokines that regulate B-cell growth and differentiation, such as IL-6, IL-9, and IL-10, are
produced by CD4+ T cells,34,94 dendritic
cells,95,96 and macrophages47,97-99 following
HIV-1 infection or in response to viral proteins, suggesting a
potential role for these cytokines in B-cell lymphomagenesis. Indeed,
high serum levels of IL-6 may be predictive of the development of
NHL.100 Once a lymphoma is established, its growth and
survival may then be sustained through paracrine and autocrine growth
loops.101,102 Interestingly, studies by Benjamin et
al103 have shown that autocrine production of IL-10 is a
feature of AIDS-associated Burkitt's lymphomas and is not seen in
sporadic or endemic cases.
Impaired immune surveillance.
There is a positive correlation between immunodeficiency, as measured
by decreasing CD4 counts, and the development of
AIDS-NHL.104 This correlation applies particularly to the
risk for developing large cell NHL, because SNCCL may develop when
immunity is relatively intact.84,100 Independent of CD4
counts, the duration of the immunodeficent state was also found to
increase the risk of developing AIDS-NHL.100 This implies
that as patients survive longer with improved retroviral treatment, the
incidence of AIDS-NHL may increase.105 Impaired
immunosurveillance as a risk factor for AIDS-NHL can be explained by an
inability of the host to contain EBV-driven B-cell expansions that may
precede malignancy, and the defective response of tumor-infiltrating T
cells which are known to play an important role in the containment of
NHL.106 In addition, generalized immunodeficiency and
consequent secondary infections would exacerbate conditions of chronic
B-cell stimulation and cytokine deregulation.
Infection with oncogenic viruses.
Viruses that have been causally linked to AIDS-NHL to date include the
herpesviruses EBV and, more recently, HHV-8. The oncogenic potential of
EBV is demonstrated by the ability of this virus to transform B cells
in vitro107 and the capacity of EBV-infected B cells to
cause lymphomas in severe combined immunodeficient (SCID)
mice.108 However, because EBV infection is not universal amongst the AIDS-NHL, the absolute role of EBV in the development of
these neoplasms is unclear. Importantly, EBV infection is highest in
primary CNS lymphomas and systemic IBL which arise in the setting of
severe immunodeficiency, and lowest in the SNCCL which frequently present while immune competence is relatively preserved. In addition, expression of the transforming antigens EBNA-2 and LMP-1 is restricted to AIDS-NHL associated with advanced
immunodeficiency.87,109 This observation strongly suggests
that, while the oncogenic potential of EBV is undisputed, the degree to
which EBV contributes to AIDS lymphomagenesis depends largely on the
degree to which virus replication and gene expression is influenced by
the host immune status.
A Role for Nonmalignant Accessory Cells in AIDS-NHL
Hematopoietic Stromal Cells Influence B Lymphopoiesis An essential accessory cell network for normal B-cell lymphopoiesis and homing in vivo, as well as for B-cell growth in vitro, is provided by the BM stroma.118-122 Depending on the conditions under which cells are cultured, BM stromal cultures can be made to be supportive of either lymphopoiesis, as in the Whitlock-Witte or related systems122-125 or myelopoiesis as in the Dexter system.126,127 Clear differences in growth factor production have not been clarified, and while IL-7 production is produced by the majority of cells in stromal cultures that support B-cell growth and differentiation,123 other factors clearly play a role in the support of B cells by marrow stromal elements. Marrow stromal cells support normal and leukemic B-cell progenitor survival and growth128,129 through mechanisms requiring attachment of the cell populations128 via adhesion molecule/ligand interactions such as VCAM-1/VLA-4,130,131 and ICAM-1/LFA-1.132 These interactions represent more than mere physical attachment. By attaching to stromal elements, B lymphoma cells induce tyrosine phosphorylation of a number of proteins in stromal cells and, perhaps of more relevance to a juxtacrine mechanism of B-cell growth, B cells induce the release of IL-6.133HIV-infected MVEC-enriched stroma supports B-lymphoma cell growth.
Stromal MVEC as well as fibroblasts are effective in supporting B-cell
proliferation.134 Indeed, McGinnes et al122
reported that MVEC-enriched stroma derived from BM spicules was more
effective at supporting B-cell growth than fibroblast-rich
aspirate-derived stroma. As previously mentioned, our group and others
have shown HIV-1 infection of stromal MVEC within the BM of patients
with AIDS and ARC.3,19 More recently, we reported that ex
vivo HIV-1 infection of MVEC-enriched stroma isolated from the BM of HIV-1 seronegative lymphoma patients induced the outgrowth and survival
of autologous B-lymphoma cells, while such stroma was not supportive of
autologous lymphoma growth in the absence of HIV-1
infection.135 In addition, culture of MVEC-enriched stroma isolated from the BM of AIDS patients with B-cell NHL promoted the
survival and outgrowth of autologous stromal-dependent malignant B
cells. These phenomena were observed for NHL of both the large and
small noncleaved B-cell types and included both EBV+ and
EBV HIV-infected brain MVEC support B-lymphoma cell growth. HIV-1 is known to infect brain microvascular endothelial cells (brain MVEC) in AIDS patients48,136 and cultured MVEC from normal brain tissue can be productively infected in vitro.49 Recent studies from our laboratory have shown that normal brain MVEC cultured in vitro were moderately supportive of the adhesion and growth of B-lymphoma cells added in coculture (Fig 4). Importantly, HIV-1 infection of these brain MVEC dramatically increased the subsequent adhesion and proliferation of cocultured B-lymphoma cells.135 Physical separation of MVEC and B cells, achieved by culturing B-lymphoma cells in transwell filter chambers over HIV-1-infected MVEC monolayers, suggested that enhanced proliferation was dependent on initial MVEC-B cell attachment. Interactions between the adhesion molecule VCAM-1 and the B-cell integrin VLA-4 play a central role in the adhesion of B cells to MVEC and other stromal elements,118,121,122,134,137,138 implicating VCAM-1 as a potential mediator of the enhanced B-lymphoma cell adhesion. Although VCAM-1 expression on brain MVEC is not induced by HIV-1 infection per se,139 expression of the cytokine receptor CD40 by brain MVEC is upregulated after HIV-1 infection of these cells.135 Recent in vitro studies have shown that CD40 is also expressed on dermal and umbilical vein endothelial cells and that CD40 triggering using soluble CD40 ligand (CD40L) increases the constitutive expression of VCAM-1 by these cells.140-142 Studies from our laboratory have shown that while CD40 triggering results in a modest induction of VCAM-1 on uninfected brain MVEC, VCAM-1 is significantly induced following CD40 triggering of HIV-1-infected MVEC.135 The ability of CD40 triggering to preferentially induce VCAM-1 on HIV-1-infected MVEC in vitro suggests that a similar mechanism could operate in vivo. While CD40L expression was first identified on activated T cells,143 additional cell types including macrophages, dendritic cells, smooth muscle cells, endothelial cells, and fibroblasts also express CD40L in certain inflammatory states.144,145 In vivo, interaction of HIV-1-infected MVEC with any of these cell types could induce VCAM-1 expression and create a microenvironment conducive to adhesion and growth of malignant B cells. In addition, because CD40L expression by malignant B cells has also been reported,135,146,147 CD40L+ B-lymphoma cells could themselves induce the adhesion phenotype. In support of this hypothesis, the adhesion and growth of a CD40L+, VLA-4+ AIDS-SNCCL cell line on HIV-1-infected MVEC is specifically inhibited by blocking functional CD40-CD40L interactions between the cells.135 Interactions between CD40 and CD40L may also play a role in the development of other types of malignancies. For example, van den Oord et al148 analyzed malignant melanoma (MM) lesions for expression of CD40 and CD40L and found that 45% of CD40+ MM coexpressed CD40L. Interestingly, patients whose tumors expressed both CD40 and CD40L had a poorer prognosis than those expressing CD40 only. The investigators in this study observed that coexpression of CD40 and CD40L usually occurred in the same area of the tumor, and proposed the existence of CD40-CD40L-mediated autocrine growth loops in the vertical growth phase of MM.
Patients with HIV-1 infection commonly develop pancytopenia, but the causes are heterogeneous and commonly iatrogenic or multifactorial. The most consistent hematopoietic defects that occur in seropositive patients as a result of HIV-1 infection per se include, first, regenerative BM failure in which on-demand hematopoiesis is suppressed, and second, a high frequency of unusually aggressive, extranodal NHLs. It is clear that neither BM failure nor lymphomagenesis results from infection of stem cells or lymphoid or myeloid progenitor cells in vivo. Indeed, it is clear that infection of such cells is not only rare29,150,151 but that the growth and differentiation of the few cells that may be infected is in no way impaired. However, infection of auxiliary cells, particularly macrophages and microvascular endothelial cells, induces a substantial alteration in the supportive function of the hematopoietic stromal tissues such that myeloid hematopoiesis is suppressed and at the same time, primitive lymphoid cell growth is augmented. We argue that a full molecular clarification of these phenomena should lead to opportunities for the rational design of preventive strategies for both regenerative failure and outgrowths of lymphoid neoplasms.
Submitted May 12, 1997;
accepted October 15, 1997.
1. Mir N, Costello C, Luckit J, Lindley R: HIV-disease and bone marrow changes: A study of 60 cases. Eur J Haematol 42:339, 1989[Medline] [Order article via Infotrieve]
2.
Costello C:
Haematological abnormalities in human immunodeficiency virus (HIV) disease.
J Clin Pathol
41:711,
1988 3. Sun NCJ, Shapshak P, Lachant NA, Hsu M, Sieger L, Schmid P, Beall G, Imagawa DT: Bone marrow examination in patients with AIDS and AIDS-related complex (ARC). Am J Clin Pathol 92:589, 1989[Medline] [Order article via Infotrieve] 4. van Elsacker-Niele AMW: Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus. Clin Infect Dis 1997 5. Wickramasinghe SN, Shiels S: Bone marrow stromal cell damage in HIV infection. Clin Lab Haematol 15:236, 1993 6. Re MC, Zauli G, Furlini G, Ranieri S, Monari P, Ramazzotti E, La Placa M: The impaired number of circulating granulocyte/macrophage progenitors (CFU-GM) in human immunodeficiency virus-type 1 infected subjects correlates with an active HIV-1 replication. Arch Virol 129:53, 1993[Medline] [Order article via Infotrieve] 7. Hillyer CD, Lackey DA, Villinger F, Winton EF, McClure HM, Ansari AA: CD34+ and CFU-GM progenitors are significantly decreased in SIVsmm9 infected rhesus macaques with minimal evidence of direct viral infection by polymerase chain reaction. Am J Hematol 43:274, 1993[Medline] [Order article via Infotrieve] 8. Steinberg HN, Anderson J, Crumpacker CS, Chatis PA: HIV infection of the BS-1 human stroma cell line: Effect on murine hematopoiesis. Virology 193:524, 1993[Medline] [Order article via Infotrieve] 9. Dietrich M, Baumgarte S, Hutert F, von Laer MD: HIV-1 infection of long term bone marrow cultures. Int Conf AIDS 8:B215, 1992 10. (abstr, suppl 1) LaRussa VF, Mosca JD, Kaushal S, Cutting MA, Kessler SW, Reid T: CD34+ stromal cell precursors are possible targets for HIV. Blood 82:414a, 1993 11. Lunardi-Iskandar Y, Georgoulias V, Bertoli AM, Augery-Bourget Y, Ammar A, Vittecoq D, Rosenbaum W, Meyer P, Jasmin C: Impaired in-vitro proliferation of hemopoietic precursors in HIV-1-infected subjects. Leuk Res 13:573, 1989[Medline] [Order article via Infotrieve] 12. Dournon E, Matheron S, Rozenbaum W, Gharakhanian S, Michon C, Girard PM, Perronne C, Salmon D, De Truchis P, Leport C: Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 2:1297, 1988[Medline] [Order article via Infotrieve]
13.
Levine AM,
Wernz JC,
Kaplan L,
Rodman N,
Cohen P,
Metroka C,
Bennett JM,
Rarick MU,
Walsh C,
Kahn J:
Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial [see comments].
JAMA
266:84,
1991
14.
Miles SA,
Mitsuyasu RT,
Moreno J,
Baldwin G,
Alton NK,
Souza L,
Glaspy JA:
Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine.
Blood
77:2109,
1991 15. Scadden DT, Bering HA, Levine JD, Bresnahan J, Evans L, Epstein C, Groopman JE: Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alpha and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 9:802, 1991[Abstract]
16.
Pluda JM,
Yarchoan R,
Smith PD,
McAtee N,
Shay LE,
Oette D,
Maha M,
Wahl SM,
Myers CE,
Broder S:
Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection.
Blood
76:463,
1990 17. (abstr) Levine AM, Cheung T, Tulpule A, Huang J, Testa M: Preliminary results of AIDS clinical trials group (ACTG) study #149: Phase II trial of ABVD chemotherapy with G-CSF in HIV infected patients with Hodgkin's disease (HD). J Acquir Immune Defic Syndr Hum Retrovirol 14:A12, 1997 18. Bagby GC: Hematopoiesis, in Stamatoyannopoulos G (ed): The Molecular Basis of Hematology. Philadelphia, PA, Saunders, 1993, p 71
19.
Moses AV,
Williams S,
Heneveld ML,
Strussenberg J,
Rarick M,
Loveless M,
Bagby G,
Nelson JA:
Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors.
Blood
87:919,
1996 20. Freedman AR, Zhu H, Levine JD, Kalams S, Scadden DT: Generation of human T lymphocytes from bone marrow CD34+ cells in vitro. Nat Med 2:46, 1996[Medline] [Order article via Infotrieve]
21.
Chelucci C,
Hassan HJ,
Locardi C,
Bulgarini D,
Pelosi E,
Mariani G,
Testa U,
Federico M,
Valtieri M,
Peschle C:
In vitro human immunodeficiency virus-1 infection of purified hematopoietic progenitors in single-cell culture.
Blood
85:1181,
1995 22. Schwartz GN, Kessler SW, Rothwell SW, Burrell LM, Reid TJ, Meltzer MS, Wright DG: Inhibitory effects of HIV-1-infected stromal cell layers on the production of myeloid progenitor cells in human long-term bone marrow cultures [published erratum appears in Exp Hematol 23:181, 1995]. Exp Hematol 22:1288, 1994[Medline] [Order article via Infotrieve] 23. Re MC, Zauli G, Gibellini D, Furlini G, Ramazzotti E, Monari P, Ranieri S, Capitani S, La Placa M: Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of AIDS patients are committed to apoptotic cell death in culture. AIDS 7:1049, 1993[Medline] [Order article via Infotrieve]
24.
Neal TF,
Holland HK,
Baum CM,
Villinger F,
Ansari AA,
Saral R,
Wingard JR,
Fleming WH:
CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1.
Blood
86:1749,
1995 25. Zauli G, Re MC, Visani G, Furlini G, Mazza P, Vignoli M, La Placa M: Evidence for a human immunodeficiency virus type 1-mediated suppression of uninfected hematopoietic (CD34+) cells in AIDS patients. J Infect Dis 166:710, 1992[Medline] [Order article via Infotrieve]
26.
Zauli G,
Re MC,
Furlini G,
Giovannini M,
La Placa M:
Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34+ cells).
J Gen Virol
73:417,
1992
27.
Molina JM,
Scadden DT,
Sakaguchi M,
Fuller B,
Woon A,
Groopman JE:
Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus.
Blood
76:2476,
1990
28.
Davis BR,
Schwartz DH,
Marx JC,
Johnson CE,
Berry JM,
Lyding J,
Merigan TC,
Zander A:
Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo.
J Virol
65:1985,
1991 29. De Luca A, Teofili L, Antinori A, Iovino MS, Mencarini P, Visconti E, Tamburrini E, Leone G, Ortona L: Haemopoietic CD34+ progenitor cells are not infected by HIV-1 in vivo but show impaired clonogenesis. Br J Haematol 85:20, 1993[Medline] [Order article via Infotrieve] 30. Bagnara GP, Zauli G, Giovannini M, Re MC, Furlini G, La Placa M: Early loss of circulating hemopoietic progenitors in HIV-1-infected subjects. Exp Hematol 18:426, 1990[Medline] [Order article via Infotrieve]
31.
Slobod KS,
Bennett TA,
Freiden PJ,
Kechli AM,
Howlett N,
Flynn PM,
Head DR,
Srivastava DK,
Boyett JM,
Brenner MK,
Garcia JV:
Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults.
Blood
88:3329,
1996
32.
Miles SA,
Mitsuyasu RT,
Lee K,
Moreno J,
Alton K,
Egrie JC,
Souza L,
Glaspy JA:
Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection.
Blood
75:2137,
1990
33.
Zauli G,
Vitale M,
Re MC,
Furlini G,
Zamai L,
Falcieri E,
Gibellini D,
Visani G,
Davis BR,
Capitani S:
In vitro exposure to human immunodeficiency virus type 1 induces apoptotic cell death of the factor-dependent TF-1 hematopoietic cell line.
Blood
83:167,
1994
34.
Oyaizu N,
Chirmule N,
Ohnishi Y,
Kalyanaraman VS,
Pahwa S:
Human immunodeficiency virus type 1 envelope glycoproteins gp120 and gp160 induce interleukin-6 production in CD4+ T-cell clones.
J Virol
65:6277,
1991 35. Shearer GM, Roilides E, Pizzo PA, Clerici M: CD4+ T helper cell function is actively suppressed in HIV infection. Int Conf AIDS 7:61, 1991
36.
Luria S,
Chambers I,
Berg P:
Expression of the type 1 human immunodeficiency virus Nef protein in T cells prevents antigen receptor-mediated induction of interleukin 2 mRNA.
Proc Natl Acad Sci USA
88:5326,
1991
37.
Smith BL,
Krushelnycky BW,
Mochly-Rosen D,
Berg P:
The HIV Nef protein associates with protein kinase C theta.
J Biol Chem
271:16753,
1996 38. Baier G, Baier-Bitterlich G, Meller N, Coggeshall KM, Giampa L, Telford D, Isakov N, Altman A: Expression and biochemical characterization of human protein kinase C-theta. Eur J Biochem 225:195, 1994[Medline] [Order article via Infotrieve] 39. Monks CRF, Kupfer H, Tamir E, Barlow A, Kupfer A: Selective modulation of protein kinase C-q during T-cell activation. Nature 385:83, 1997[Medline] [Order article via Infotrieve] 40. Stella CC, Ganser A, Hoelzer D: Defective in vitro growth of the hemopoietic progenitor cells in the acquired immunodeficiency syndrome. J Clin Invest 80:286, 1987
41.
Molina JM,
Scadden DT,
Amirault C,
Woon A,
Vannier E,
Dinarello CA,
Groopman JE:
Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells.
J Virol
64:2901,
1990
42.
Chehimi J,
Starr SE,
Frank I,
D'Andrea A,
Ma X,
MacGregor RR,
Sennelier J,
Trinchieri G:
Impaired interleukin 12 production in human immunodeficiency virus-infected patients.
J Exp Med
179:1361,
1994 43. Sperber K, Hamrang G, Louie MJ, Kalb T, Banerjee R, Choi HS, Paronetto F, Mayer L: Progressive impairment of monocytic function in HIV-1-infected human macrophage hybridomas. AIDS Res Hum Retroviruses 9:657, 1993[Medline] [Order article via Infotrieve] 44. Bagby GC: Interleukin 1 and hematopoiesis. Blood Rev 3:152, 1989[Medline] [Order article via Infotrieve]
45.
Tripp CS,
Wolf SF,
Unanue ER:
Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist.
Proc Natl Acad Sci USA
90:3725,
1993 46. Wu C-Y, Demeure C, Kiniwa M, Gately M, Delespesse G: IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells. J Immunol 151:1938, 1993[Abstract]
47.
Esser R,
Glienke W,
Von Briesen H,
Rubsamen-Waigmann H,
Andreesen R:
Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus.
Blood
88:3474,
1996
48.
Wiley CA,
Schrier RD,
Nelson JA,
Lampert PW,
Oldstone MB:
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients.
Proc Natl Acad Sci USA
83:7089,
1986
49.
Moses AV,
Bloom FE,
Pauza CD,
Nelson JA:
HIV infection of human brain capillary endothelial cells occurs via a CD4/GAL C-independent mechanism.
Proc Natl Acad Sci USA
90:10474,
1993
50.
Steffan AM,
Lafon ME,
Gendrault JL,
Schweitzer C,
Royer C,
Jaeck D,
Arnaud JP,
Schmitt MP,
Aubertin AM,
Kirn A:
Primary cultures of endothelial cells from the human liver sinusoid are permissive for human immunodeficiency virus type 1.
Proc Natl Acad Sci USA
89:1582,
1992 51. Green DF, Resnick L, Bourgoignie JJ: HIV infects glomerular endothelial and mesangial but not epithelial cells in vitro. Kidney Int 41:956, 1992[Medline] [Order article via Infotrieve]
52.
Bahner I,
Kearns K,
Coutinho S,
Leonard EH,
Kohn DB:
Infection of human marrow stroma by human immunodeficiency virus-1 (HIV-1) is both required and sufficient for HIV-1-induced hematopoietic suppression in vitro: Demonstration by gene modification of primary human stroma.
Blood
90:1787,
1997 53. Bagby GC: T-lymphocytes which inhibit granulopoiesis in two neutropenic patients are of the cytotoxic suppressor (OKT3+, OKT8+) subset. J Clin Invest 68:1597, 1981 54. Bagby GC, Lawrence JH, Neerhout RC: Autoimmune granulopoietic failure: Identification of T-lymphocyte-mediated inhibition of granulopoiesis and prednisone responsiveness using in vitro techniques. N Engl J Med 309:1073, 1983[Abstract] 55. Geissler RG, Rossol R, Mentzel U, Ottmann OG, Klein AS, Gute P, Helm EB, Hoelzer D, Ganser A: Gamma delta-T cell-receptor-positive lymphocytes inhibit human hematopoietic progenitor cell growth in HIV type 1-infected patients. AIDS Res Hum Retroviruses 12:577, 1996[Medline] [Order article via Infotrieve] 56. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV: Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 70:199, 1996[Abstract]
57.
Nagafuji K,
Shibuya T,
Harada M,
Mizuno S,
Takenaka K,
Miyamoto T,
Okamura T,
Gondo H,
Niho Y:
Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells.
Blood
86:883,
1995
58.
Maciejewski J,
Selleri C,
Anderson S,
Young NS:
Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro.
Blood
85:3183,
1995 59. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS: Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol 91:245, 1995[Medline] [Order article via Infotrieve]
60.
Rathbun RK,
Faulkner GR,
Ostroski MH,
Christianson TA,
Hughes G,
Jones G,
Cahn R,
Maziarz RT,
Royle G,
Keeble W,
Heinrich MC,
Grompe M,
Tower PA,
Bagby GC:
Inactivation of the Fanconi anemia group C (FAC) gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells.
Blood
90:974,
1997 61. Marandin A, Canque B, Coulombel L, Gluckman JC, Vainchenker W, Louache F: In vitro infection of bone marrow-adherent cells by human immunodeficiency virus type 1 (HIV-1) does not alter their ability to support hematopoiesis. Virology 213:245, 1995[Medline] [Order article via Infotrieve] 62. Wang Z, Goldberg MA, Scadden DT: HIV-1 suppresses erythropoietin production in vitro. Exp Hematol 21:683, 1993[Medline] [Order article via Infotrieve] 63. Ziegler JL, Drew WL, Miner RC, Mintz L, Rosenbaum E, Gershow J, Lennette ET, Greenspan J, Shillitoe E, Beckstead J, Casavant C, Yamamoto K: Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet 2:631, 1982[Medline] [Order article via Infotrieve] 64. Beral V, Peterman T, Berkelman R, Jaffe H: AIDS-associated non-Hodgkin lymphoma [see comments]. Lancet 337:805, 1991[Medline] [Order article via Infotrieve]
65.
Karp JE,
Broder S:
Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas.
Cancer Res
51:4743,
1991
66.
Levine AM:
AIDS-related malignancies: The emerging epidemic.
J Natl Cancer Inst
85:1382,
1993 67. Astrin SM, Schattner E, Laurence J, Lebman RI, Rodriguez-Alfageme C: Does HIV infection of B lymphocytes initiate AIDS lymphoma? Detection by PCR of viral sequences in lymphoma tissue. Curr Top Microbiol Immunol 182:399, 1992[Medline] [Order article via Infotrieve] 68. Prevot S, Raphael M, Fournier JG, Diebold J: Detection by in situ hybridization of HIV and c-myc RNA in tumour cells of AIDS-related B-cell lymphomas. Histopathology 22:151, 1993[Medline] [Order article via Infotrieve]
69.
Subar M,
Neri A,
Inghirami G,
Knowles DM,
Dalla-Favera R:
Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma.
Blood
72:667,
1988 70. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, Karkov J, Black F, Skinhoj P, Pedersen C: AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol 138:149, 1991[Abstract]
71.
Groopman JE,
Sullivan JL,
Mulder C,
Ginsburg D,
Orkin SH,
O'Hara CJ,
Falchuk K,
Wong-Staal F,
Gallo RC:
Pathogenesis of B cell lymphoma in a patient with AIDS.
Blood
67:612,
1986
72.
Pelicci PG,
Knowles DM 2d,
Arlin ZA,
Wieczorek R,
Luciw P,
Dina D,
Basilico C,
Dalla-Favera R:
Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis.
J Exp Med
164:2049,
1986
73. (suppl 19)
Kinlen L:
Immunosuppressive therapy and acquired immunological disorders.
Cancer Res
52:5474s,
1992 74. (abstr) Biggar RJ, Rosenberg PS, Cote T, Goedert JJ: Non Hodgkin's lymphoma in AIDS: findings from linking AIDS and cancer registries. J Acquir Immune Defic Syndr Hum Retrovirol 14:A43, 1997
75.
Levine AM,
Shibata D,
Sullivan-Halley J,
Nathwani B,
Brynes R,
Slovak ML,
Mahterian S,
Riley CL,
Weiss L,
Levine PH:
Epidemiological and biological study of acquired immunodeficiency syndrome-related lymphoma in the County of Los Angeles: Preliminary results.
Cancer Res
52:5482s,
1992
76.
Delecluse HJ,
Raphael M,
Magaud JP,
Felman P,
Alsamad IA,
Bornkamm GW,
Lenoir GM:
Variable morphology of human immunodeficiency virus-associated lymphomas with c-myc rearrangements. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors, I.
Blood
82:552,
1993 77. Chadburn A, Cesarman E, Jagirdar J, Subar M, Mir RN, Knowles DM: CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. Cancer 72:3078, 1993[Medline] [Order article via Infotrieve] 78. Carbone A, Gloghini A, Vaccher E, Zagonel V, Pastore C, Dalla Palma P, Branz F, Saglio G, Volpe R, Tirelli U, Gaidano G: Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. Br J Haematol 94:533, 1996[Medline] [Order article via Infotrieve]
79.
Cesarman E,
Chang Y,
Moore PS,
Said JW,
Knowles DM:
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas [see comments].
N Engl J Med
332:1186,
1995
80.
Delecluse HJ,
Anagnostopoulos I,
Dallenbach F,
Hummel M,
Marafioti T,
Schneider U,
Huhn D,
Schmidt-Westhausen A,
Reichart PA,
Gross U,
Stein H:
Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection.
Blood
89:1413,
1997
81.
Carbone A,
Gloghini A,
Canzonieri V,
Tirelli U:
AIDS-related extranodal non-Hodgkin's lymphomas with plasma cell differentiation.
Blood
90:1337,
1997 82. Raphael M, Gentilhomme O, Tulliez M, Byron PA, Diebold J: Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors. Arch Pathol Lab Med 115:15, 1991[Medline] [Order article via Infotrieve] 83. Lowenthal DA, Straus DJ, Campbell SW, Gold JW, Clarkson BD, Koziner B: AIDS-related lymphoid neoplasia. The Memorial Hospital experience. Cancer 61:2325, 1988[Medline] [Order article via Infotrieve] 84. Pedersen C, Gerstoft J, Lundgren JD, Skinhoj P, Bottzauw J, Geisler C, Hamilton-Dutoit SJ, Thorsen S, Lisse I, Ralfkiaer E: HIV-associated lymphoma: Histopathology and association with Epstein-Barr virus genome related to clinical, immunological and prognostic features. Eur J Cancer 27:1416, 1991
85.
Shibata D,
Weiss LM,
Hernandez AM,
Nathwani BN,
Bernstein L,
Levine AM:
Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus.
Blood
81:2102,
1993
86.
Shiramizu B,
Herndier B,
Meeker T,
Kaplan L,
McGrath M:
Molecular and immunophenotypic characterization of AIDS-associated, Epstein-Barr virus-negative, polyclonal lymphoma [see comments].
J Clin Oncol
10:383,
1992
87.
Carbone A,
Tirelli U,
Gloghini A,
Volpe R,
Boiocchi M:
Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression.
J Clin Oncol
11:1674,
1993
88.
Camilleri-Broet S,
Davi F,
Feuillard J,
Bourgeois C,
Seilhean D,
Hauw JJ,
Raphael M:
High expression of latent membrane protein 1 of Epstein-Barr virus and BCL-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas.
Blood
86:432,
1995
89.
Ballerini P,
Gaidano G,
Gong JZ,
Tassi V,
Saglio G,
Knowles DM,
Dalla-Favera R:
Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma.
Blood
81:166,
1993
90.
Gaidano G,
Lo Coco F,
Ye BH,
Shibata D,
Levine AM,
Knowles DM,
Dalla-Favera R:
Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: Association with diffuse large-cell subtype.
Blood
84:397,
1994 91. Boyle MJ, Goldstein DA, Frazer IH, Sculley TB: Managing HIV. Part 3: Mechanisms of disease. 3.6. How HIV promotes malignancies. Med J Aust 164:230, 1996[Medline] [Order article via Infotrieve] 92. Fauci AS, Schnittman SM, Poli G, Koenig S, Pantaleo G: Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Int Med 114:678, 1991
93.
Riboldi P,
Gaidano G,
Schettino EW,
Steger TG,
Knowles DM,
Dalla-Favera R,
Casali P:
Two acquired immunodeficiency syndrome-associated Burkitt's lymphomas produce specific anti-i IgM cold agglutinins using somatically mutated VH4-21 segments.
Blood
83:2952,
1994 94. Chirmule N, Kalyanaraman VS, Lederman S, Oyaizu N, Yagura H, Yellin MJ, Chess L, Pahwa S: HIV-gp 160-induced T cell-dependent B cell differentiation. Role of T cell-B cell activation molecule and IL-6. J Immunol 150:2478, 1993[Abstract] 95. Ghanekar S, Zheng L, Logar A, Navratil J, Borowski L, Gupta P, Rinaldo C: Cytokine expression by human peripheral blood dendritic cells stimulated in vitro with HIV-1 and herpes simplex virus. J Immunol 157:4028, 1996[Abstract] 96. Ludewig B, Gelderblom HR, Becker Y, Schäfer A, Pauli G: Transmission of HIV-1 from productively infected mature Langerhans cells to primary CD4+ T lymphocytes results in altered T cell responses with enhanced production of IFN-gamma and IL-10. Virology 215:51, 1996[Medline] [Order article via Infotrieve] 97. Clouse KA, Cosentino LM, Weih KA, Pyle SW, Robbins PB, Hochstein HD, Natarajan V, Farrar WL: The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. J Immunol 147:2892, 1991[Abstract] 98. Trentin L, Garbisa S, Zambello R, Agostini C, Caenazzo C, Di Francesco C, Cipriani A, Francavilla E, Semenzato G: Spontaneous production of interleukin-6 by alveolar macrophages from human immunodeficiency virus type 1-infected patients. J Infect Dis 166:731, 1992[Medline] [Order article via Infotrieve] 99. Gan HX, Ruef C, Hall BF, Tobin E, Remold HG, Mellors JW: Interleukin-6 expression in primary macrophages infected with human immunodeficiency virus-1 (HIV-1). AIDS Res Hum Retroviruses 7:671, 1991[Medline] [Order article via Infotrieve]
100.
Pluda JM,
Venzon DJ,
Tosato G,
Lietzau J,
Wyvill K,
Nelson DL,
Jaffe ES,
Karp JE,
Broder S,
Yarchoan R:
Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.
J Clin Oncol
11:1099,
1993
101.
Emilie D,
Coumbaras J,
Raphael M,
Devergne O,
Delecluse HJ,
Gisselbrecht C,
Michiels JF,
Van Damme J,
Taga T,
Kishimoto T:
Interleukin-6 production in high-grade B lymphomas: Correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients.
Blood
80:498,
1992 102. Emilie D, Touitou R, Raphael M, Peuchmaur M, Devergnee O, Rea D, Coumbraras J, Crevon MC, Edelman L, Joab I: In vivo production of interleukin-10 by malignant cells in AIDS lymphomas. Eur J Immunol 22:2937, 1992[Medline] [Order article via Infotrieve]
103.
Benjamin D,
Knobloch TJ,
Dayton MA:
Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10.
Blood
80:1289,
1992 104. Levine AM, Sullivan-Halley J, Pike MC, Rarick MU, Loureiro C, Bernstein-Singer M, Willson E, Brynes R, Parker J, Rasheed S: Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival [see comments]. Cancer 68:2466, 1991[Medline] [Order article via Infotrieve] 105. Kaplan LD: The lymphoma project report. Current issues in research and treatment of AIDS-associated lymphoma. Pamphlet published by The Treatment Action Group, New York, NY, 1995 106. Ramsay AD, Smith WJ, Isaacson PG: T-cell-rich B-cell lymphoma. Am J Surg Pathol 12:433, 1988[Medline] [Order article via Infotrieve] 107. Kieff E, Liebowitz D: Oncogenesis by herpesviruses, in Weinberg RA (ed): Oncogenes and the Molecular Origins of Cancer. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989, p 259
108.
Rowe M,
Young LS,
Crocker J,
Stokes H,
Henderson S,
Rickinson AB:
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: Implications for the pathogenesis of EBV-positive lymphomas in man.
J Exp Med
173:147,
1991
109.
Hamilton-Dutoit SJ,
Raphael M,
Audouin J,
Diebold J,
Lisse I,
Pedersen C,
Oksenhendler E,
Marelle L,
Pallesen G:
In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site.
Blood
82:619,
1993
110.
Chang Y,
Cesarman E,
Pessin MS,
Lee F,
Culpepper J,
Knowles DM,
Moore PS:
Identification of herpesvirus-like DNA sequences in AIDS- associated Kaposi's sarcoma.
Science
266:1865,
1994
111.
Moore PS,
Chang Y:
Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection [see comments].
N Engl J Med
332:1181,
1995 112. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett FE, Aldam DM, Denton AS: Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma [see comments]. Lancet 346:799, 1995[Medline] [Order article via Infotrieve] 113. Lipkin M, Higgins P: Biological markers of cell proliferation and differentiation in human gastrointestinal diseases. Adv Cancer Res 50:1, 1988[Medline] [Order article via Infotrieve] 114. Gaidano G, Pastore C, Gloghini A, Cusini M, Nomdedeu J, Volpe G, Capello D, Vaccher E, Bordes R, Tirelli U, Saglio G, Carbone A: Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. AIDS 10:941, 1996[Medline] [Order article via Infotrieve] 115. Cesarman E, Nador RG, Bai F, Bohenzky RA, Russo JJ, Moore PS, Chang Y, Knowles DM: Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J Virol 70:8218, 1996[Abstract]
116.
Moore PS,
Boshoff C,
Weiss RA,
Chang Y:
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.
Science
274:1739,
1996
117.
Rettig MB,
Ma HJ,
Vescio RA,
Pold M,
Schiller G,
Belson D,
Savage A,
Nishikubo C,
Wu C,
Fraser J,
Said JW,
Berenson JR:
Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients [see comments].
Science
276:1851,
1997
118.
Tang J,
Scott G,
Ryan DH:
Subpopulations of bone marrow fibroblasts support VLA-4-mediated migration of B-cell precursors.
Blood
82:3415,
1993 119. Jacobsen K, Osmond DG: Microenvironmental organization and stromal cell associations of B lymphocyte precursor cells in mouse bone marrow. Eur J Immunol 20:2395, 1990[Medline] [Order article via Infotrieve] 120. Wolf ML, Buckley JA, Goldfarb A, Law CL, LeBien TW: Development of a bone marrow culture for maintenance and growth of normal human B cell precursors. J Immunol 147:3324, 1991[Abstract]
121.
Simmons PJ,
Masinovsky B,
Longenecker BM,
Berenson R,
Torok-Storb B,
Gallatin WM:
Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells.
Blood
80:388,
1992 122. McGinnes K, Quesniaux V, Hitzler J, Paige C: Human B-lymphopoiesis is supported by bone marrow-derived stromal cells. Exp Hematol 19:294, 1991[Medline] [Order article via Infotrieve] 123. Witte PL, Frantsve LM, Hergott M, Rahbe SM: Cytokine production and heterogeneity of primary stromal cells that support B lymphopoiesis. Eur J Immunol 23:1809, 1993[Medline] [Order article via Infotrieve] 124. Whitlock CA, Witte ON: Long-term culture of murine bone marrow precursors of B lymphocytes. Methods Enzymol 150:275, 1987[Medline] [Order article via Infotrieve]
125.
Whitlock CA,
Witte ON:
Long-term culture of B lymphocytes and their precursors from murine bone marrow.
Proc Natl Acad Sci USA
79:3608,
1982 126. Dexter TM: Haemopoiesis in long-term bone marrow cultures. A review. Acta Haematol 62:299, 1979[Medline] [Order article via Infotrieve] 127. Dexter TM, Allen TD, Lajtha LG: Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 91:335, 1977[Medline] [Order article via Infotrieve]
128.
Manabe A,
Murti KG,
Coustan-Smith E,
Kumagai M,
Behm FG,
Raimondi SC,
Campana D:
Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells.
Blood
83:758,
1994 129. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV: Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 92:97, 1996[Medline] [Order article via Infotrieve]
130.
Miyake K,
Weissman IL,
Greenberger JS,
Kincade PW:
Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis.
J Exp Med
173:599,
1991 131. Juneja HS, Schmalsteig FC, Lee S, Chen J: Vascular cell adhesion molecule-1 and VLA-4 are obligatory adhesion proteins in the heterotypic adherence between human leukemia/lymphoma cells and marrow stromal cells. Exp Hematol 21:444, 1993[Medline] [Order article via Infotrieve] 132. Koopman G, Keehnen RM, Lindhout E, Newman W, Shimizu Y, van Seventer GA, de Groot C, Pals ST: Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol 152:3760, 1994[Abstract] 133. Jarvis LJ, LeBien TW: Stimulation of human bone marrow stromal cell tyrosine kinases and IL-6 production by contact with B lymphocytes. J Immunol 155:2359, 1995[Abstract]
134.
Dittel BN,
McCarthy JB,
Wayner EA,
LeBien TW:
Regulation of human B-cell precursor adhesion to bone marrow stromal cells by cytokines that exert opposing effects on the expression of vascular cell adhesion molecule-1 (VCAM-1).
Blood
81:2272,
1993 135. Moses AV, Williams SE, Strussenberg JG, Ostroski ML, Bagby GC, Nelson J: HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B cell lymphomas. Nature Med 3:1242, 1997[Medline] [Order article via Infotrieve] 136. Bagasra O, Lavi E, Bobroski L, Khalili K, Pestaner JP, Tawadros R, Pomerantz RJ: Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: Identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 10:573, 1996[Medline] [Order article via Infotrieve] 137. Ryan DH, Nuccie BL, Abboud CN, Winslow JM: Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells. J Clin Invest 88:995, 1991 138. Freedman AS: Expression and function of adhesion receptors on normal B cells and B cell non-Hodgkin's lymphomas. Semin Hematol 30:318, 1993[Medline] [Order article via Infotrieve]
139.
Moses AV,
Nelson JA:
HIV infection of human brain capillary endothelial cells
140.
Hollenbaugh D,
Mischel-Petty N,
Edwards CP,
Simon JC,
Denfeld RW,
Kiener PA,
Aruffo A:
Expression of functional CD40 by vascular endothelial cells.
J Exp Med
182:33,
1995
141.
Karmann K,
Hughes CC,
Schechner J,
Fanslow WC,
Pober JS:
CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression.
Proc Natl Acad Sci USA
92:4342,
1995
142.
Yellin MJ,
Brett J,
Baum D,
Matsushima A,
Szabolcs M,
Stern D,
Chess L:
Functional interactions of T cells with endothelial cells: The role of CD40L-CD40-mediated signals.
J Exp Med
182:1857,
1995
143.
Noelle RJ,
Roy M,
Shepherd DM,
Stamenkovic I,
Ledbetter JA,
Aruffo A:
A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells.
Proc Natl Acad Sci USA
89:6550,
1992
144.
Cocks BG,
De Waal Malefyt R,
Galizzi JP,
De Vries JE,
Aversa G:
IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand.
Int Immunol
5:657,
1993
145.
Mach F,
Schonbeck U,
Sukhova GK,
Bourcier T,
Bonnefoy JY,
Pober JS,
Libby P:
Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis.
Proc Natl Acad Sci USA
94:1931,
1997 146. Grammer AC, Bergman MC, Miura Y, Fujita K, Davis LS, Lipsky PE: The CD40 ligand expressed by human B cell costimulates B cell responses. J Immunol 154:4996, 1995[Abstract] 147. Pinchuk LM, Klaus SJ, Magaletti DM, Pinchuk GV, Norsen JP, Clark EA: Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. J Immunol 157:4363, 1996[Abstract] 148. van den Oord JJ, Maes A, Stas M, Nuyts J, Battocchio S, Kasran A, Garmyn M, De Wever I, De Wolf-Peeters C: CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 149:1953, 1996[Abstract] 149. Larson AW, LeBien TW: Cross-linking CD40 on human B cell precursors inhibits or enhances growth depending on the stage of development and the IL costimulus. J Immunol 153:584, 1994[Abstract] 150. Stanley SK, Kessler SW, Justement JS, Schnittman SM, Greenhouse JJ, Brown CC, Musongela L, Musey K, Kapita B, Fauci AS: CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol 149:689, 1992[Abstract] 151. Kearns K, Bahner I, Bauer G, Wei S, Valdez P, Wheeler S, Woods L, Miller R, Casciato D, Galpin J, Church J, Kohn DB: Suitability of bone marrow from HIV-1-infected donors for retrovirus-mediated gene transfer. Human Gene Ther 8:301, 1997[Medline] [Order article via Infotrieve] 152. Blazevic V, Heino M, Lagerstedt A, Ranki A, Krohn KJ: Interleukin-10 gene expression induced by HIV-1 Tat and Rev in the cells of HIV-1 infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 13:208, 1996[Medline] [Order article via Infotrieve] 153. Takeshita S, Breen EC, Ivashchenko M, Nishanian PG, Kishimoto T, Vredevoe DL, Martinez-Maza O: Induction of IL-6 and IL-10 production by recombinant HIV-1 envelope glycoprotein 41 (gp41) in the THP-1 human monocytic cell line. Cell Immunol 165:234, 1995[Medline] [Order article via Infotrieve]
154.
De Waal Malefyt R,
Abrams J,
Bennett B,
Figdor CG,
De Vries JE:
Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.
J Exp Med
174:1209,
1991 155. Wang P, Wu P, Siegel MI, Egan RW, Billah MM: IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 153:811, 1994[Abstract] 156. Cox RA, Anders GT, Cappelli PJ, Johnson JE, Blanton HM, Seaworth BJ, Treasure RL: Production of tumor necrosis factor-alpha and interleukin-1 by alveolar macrophages from HIV-1-infected persons. AIDS Res Hum Retroviruses 6:431, 1990[Medline] [Order article via Infotrieve] 157. Navikas V, Link J, Wahren B, Persson C, Link H: Increased levels of interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) mRNA expressing blood mononuclear cells in human HIV infection. Clin Exp Immunol 96:59, 1994[Medline] [Order article via Infotrieve] 158. Rossol-Voth R, Klein SA, Geissler G, Gute P, Helm EB, Falke D, Hoelzer D: TNF-alpha produced by gamma delta-T-cells as the pivotal pathogenic factor in HIV-infection for the depletion of CD4-pos. T-cells and the inhibition of the hematopoiesis. Int Conf AIDS 8:A69, 1992 159. Husain SR, Leland P, Aggarwal BB, Puri RK: Transcriptional up-regulation of interleukin 4 receptors by human immunodeficiency virus type 1 tat gene. AIDS Res Hum Retroviruses 12:1349, 1996[Medline] [Order article via Infotrieve] 160. Brady HJ, Abraham DJ, Pennington DJ, Miles CG, Jenkins S, Dzierzak EA: Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice. J Virol 69:7622, 1995[Abstract] 161. Gallicchio VS, Tse KF, Morrow J, Hughes NK: Suppression of hematopoietic support function is associated with overexpression of interleukin-4 and transforming growth factor-b1 in LP-BM5 murine-leukemia-virus-infected stromal cell lines. Acta Haematol 95:204, 1996[Medline] [Order article via Infotrieve] 162. Gautam SC, Noth CJ, Janakiraman N, Pindolia KR, Chapman RA: Induction of chemokine mRNA in bone marrow stromal cells: Modulation by TGF-beta 1 and IL-4. Exp Hematol 23:482, 1995[Medline] [Order article via Infotrieve] 163. Sunila I, Vaccarezza M, Pantaleo G, Fauci AS, Orenstein JM: Gp120 is present on the plasma membrane of apoptotic CD4 cells prepared from lymph nodes of HIV-1-infected individuals: An immunoelectron microscopic study. AIDS 11:27, 1997[Medline] [Order article via Infotrieve]
164.
Kolesnitchenko V,
Wahl LM,
Tian H,
Sunila I,
Tani Y,
Hartmann DP,
Cossman J,
Raffeld M,
Orenstein J,
Samelson LE:
Human immunodeficiency virus 1 envelope-initiated G2-phase programmed cell death.
Proc Natl Acad Sci USA
92:11889,
1995
165.
Takenaka K,
Nagafuji K,
Harada M,
Miyamoto T,
Makino S,
Gondo H,
Okamura T,
Niho Y:
In vitro expansion of hematopoietic progenitor cells induces functional expression of fas antigen (CD95).
Blood
88:2871,
1996
166.
Barcena A,
Park SW,
Banapour B,
Muench MO,
Mechetner E:
Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver.
Blood
88:2013,
1996 167. Maciejewski JP, Weichold FF, Young NS: HIV-1 suppression of hematopoiesis in vitro mediated by envelope glycoprotein and TNF-alpha. J Immunol 153:4303, 1994[Abstract] 168. Roux-Lombard P, Modoux C, Cruchaud A, Dayer J-M: Purified blood monocytes from HIV 1-infected patients produce high levels of TNFa and IL-1. Clin Immunol Immunopathol 50:374, 1989[Medline] [Order article via Infotrieve]
169.
Zauli G,
Davis BR,
Re MC,
Visani G,
Furlini G,
La Placa M:
tat Protein stimulates production of transforming growth factor-b1 by marrow macrophages: A potential mechanism for human immunodeficiency virus-1-induced hematopoietic suppression.
Blood
80:3036,
1992 170. Lotz M, Seth P: TGF beta and HIV infection. Ann NY Acad Sci 685:501, 1993[Medline] [Order article via Infotrieve] 171. Denis M, Ghadirian E: Alveolar macrophages from subjects infected with HIV-1 express macrophage inflammatory protein-1a (MIP-1a): Contribution to the CD8+ alveolitis. Clin Exp Immunol 96:187, 1994[Medline] [Order article via Infotrieve]
172.
Zauli G,
Vitale M,
Gibellini D,
Capitani S:
Inhibition of purified CD34+ hematopoietic progenitor cells by human immunodeficiency virus 1 or gp120 mediated by endogenous transforming growth factor beta 1.
J Exp Med
183:99,
1996
173.
Folks TM,
Kessler SW,
Orenstein JM,
Justement JS,
Jaffe ES,
Fauci AS:
Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow.
Science
242:919,
1988
174.
Steinberg HN,
Crumpacker CS,
Chatis PA:
In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus.
J Virol
65:1765,
1991 175. Kojouharoff G, Ottmann OG, Von Briesen H, Geissler G, R:ubsamen-Waigmann H, Hoelzer D, Ganser A: Infection of granulocyte/monocyte progenitor cells with HIV1. Res Virol 142:151, 1991 176. Zauli G, Re MC, Giovannini M, Bagnara GP, Furlini G, Ranieri S, La Placa M: Effect of human immunodeficiency virus type 1 on CD34+ cells. Ann NY Acad Sci 628:273, 1991[Medline] [Order article via Infotrieve] 177. Zauli G, Re MC, Visani G, Furlini G, La Placa M: Inhibitory effect of HIV-1 envelope glycoproteins gp120 and gp160 on the in vitro growth of enriched (CD34+) hematopoietic progenitor cells. Arch Virol 122:271, 1992[Medline] [Order article via Infotrieve] 178. Calenda V, Sebahoun G, Chermann JC: Modulation of normal human erythropoietic progenitor cells in long-term liquid cultures after HIV-1 infection. AIDS Res Hum Retroviruses 8:61, 1992[Medline] [Order article via Infotrieve] 179. Cen D, Zauli G, Szarnicki R, Davis BR: Effect of different human immunodeficiency virus type-1 (HIV-1) isolates on long-term bone marrow haemopoiesis Effect of different human immunodeficiency virus type-1 (HIV-1) isolates on long-term bone marrow haemopoiesis. Br J Haematol 85:596, 1993[Medline] [Order article via Infotrieve] 180. Schwartz GN, Kessler SW, Szabo JM, Burrell LM, Francis ML: Negative regulators may mediate some of the inhibitory effects of HIV-1 infected stromal cell layers on erythropoiesis and myelopoiesis in human bone marrow long term cultures. J Leukoc Biol 57:948, 1995[Abstract]
181.
Kaushal S,
La Russa VF,
Gartner S,
Kessler S,
Perfetto S,
Yu Z,
Ritchey DW,
Xu J,
Perera P,
Kim J,
Reid T,
Mayers DL,
St. Louis D,
Mosca JD:
Exposure of human CD34+ cells to human immunodeficiency virus type 1 does not influence their expansion and proliferation of hematopoietic progenitors in vitro.
Blood
88:130,
1996 182. Donahue RE, Johnson MM, Zon LI, Clark SC, Groopman JE: Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. Nature 326:200, 1987[Medline] [Order article via Infotrieve]
183.
Von Laer D,
Hufert FT,
Fenner TE,
Schwander S,
Dietrich M,
Schmitz H,
Kern P:
CD34+ hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus.
Blood
76:1281,
1990 184. Ganser A, Ottmann OG, Von Briesen H, Volkers B, Rubsamen-Waigmann H, Hoelzer D: Changes in the haematopoietic progenitor cell compartment in the acquired immunodeficiency syndrome. Res Virol 141:185, 1990[Medline] [Order article via Infotrieve]
185.
Zauli G,
Re MC,
Davis B,
Sen L,
Visani G,
Gugliotta L,
Furlini G,
La Placa M:
Impaired in vitro growth of purified (CD34+) hematopoietic progenitors in human immunodeficiency virus-1 seropositive thrombocytopenic individuals.
Blood
79:2680,
1992
186.
Louache F,
Henri A,
Bettaieb A,
Oksenhendler E,
Raguin G,
Tulliez M,
Vainchenker W:
Role of human immunodeficiency virus replication in defective in vitro growth of hematopoietic progenitors.
Blood
80:2991,
1992 187. Kaczmarski RS, Davison F, Blair E, Sutherland S, Moxham J, McManus T, Mufti GJ: Detection of HIV in haemopoietic progenitors. Br J Haematol 82:764, 1992[Medline] [Order article via Infotrieve] 188. Dallalio G, North M, Means RT Jr: Inhibition of marrow CFU-E colony formation from human immunodeficiency virus-infected patients by b- and gamma-interferon. Am J Hematol 53:118, 1996[Medline] [Order article via Infotrieve]
189.
Marandin A,
Katz A,
Oksenhendler E,
Tulliez M,
Picard F,
Vainchenker W,
Louache F:
Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection.
Blood
88:4568,
1996
© 1998 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. Paiardini, B. Cervasi, J. C. Engram, S. N. Gordon, N. R. Klatt, A. Muthukumar, J. Else, R. S. Mittler, S. I. Staprans, D. L. Sodora, et al. Bone marrow-based homeostatic proliferation of mature T cells in nonhuman primates: implications for AIDS pathogenesis Blood, January 15, 2009; 113(3): 612 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Reeves and P. N. Fultz Characterization of Plasmacytoid Dendritic Cells in Bone Marrow of Pig-Tailed Macaques Clin. Vaccine Immunol., January 1, 2008; 15(1): 35 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Magalhaes, B. Greenberg, H. Hansen, and M. Glick Comorbidities in older patients with HIV: A retrospective study J Am Dent Assoc, November 1, 2007; 138(11): 1468 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Redd, A. Avalos, and M. Essex Infection of hematopoietic progenitor cells by HIV-1 subtype C, and its association with anemia in southern Africa Blood, November 1, 2007; 110(9): 3143 - 3149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Meissner, M. Rutkowski, A. L. Harmsen, S. Han, and A. G. Harmsen Type I Interferon Signaling and B Cells Maintain Hemopoiesis during Pneumocystis Infection of the Lung J. Immunol., May 15, 2007; 178(10): 6604 - 6615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Watanabe, K. Terashima, S. Ohta, S. Horibata, M. Yajima, Y. Shiozawa, M. Z. Dewan, Z. Yu, M. Ito, T. Morio, et al. Hematopoietic stem cell-engrafted NOD/SCID/IL2R{gamma}null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses Blood, January 1, 2007; 109(1): 212 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Levine, R. Karim, W. Mack, D. J. Gravink, K. Anastos, M. Young, M. Cohen, M. Newman, M. Augenbraun, S. Gange, et al. Neutropenia in Human Immunodeficiency Virus Infection: Data From the Women's Interagency HIV Study. Arch Intern Med, February 27, 2006; 166(4): 405 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P Galvani The role of mutation accumulation in HIV progression Proc R Soc B, September 7, 2005; 272(1574): 1851 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Holm and D. Gabuzda Distinct Mechanisms of CD4+ and CD8+ T-Cell Activation and Bystander Apoptosis Induced by Human Immunodeficiency Virus Type 1 Virions J. Virol., May 15, 2005; 79(10): 6299 - 6311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Thiebot, B. Vaslin, S. Derdouch, J.-M. Bertho, F. Mouthon, S. Prost, G. Gras, P. Ducouret, D. Dormont, and R. Le Grand Impact of bone marrow hematopoiesis failure on T-cell generation during pathogenic simian immunodeficiency virus infection in macaques Blood, March 15, 2005; 105(6): 2403 - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Monteiro, A. Benjamin, E. S. Costa, M. A. Barcinski, and A. Bonomo Normal hematopoiesis is maintained by activated bone marrow CD4+ T cells Blood, February 15, 2005; 105(4): 1484 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamakami, M. Honda, M. Takei, Y. Ami, N. Kitamura, S. Nishinarita, S. Sawada, and T. Horie Early Bone Marrow Hematopoietic Defect in Simian/Human Immunodeficiency Virus C2/1-Infected Macaques and Relevance to Advance of Disease J. Virol., October 15, 2004; 78(20): 10906 - 10910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Koka, C. M. R. Kitchen, and S. T. Reddy Targeting c-Mpl for Revival of Human Immunodeficiency Virus Type 1-Induced Hematopoietic Inhibition When CD34+ Progenitor Cells Are Re-Engrafted into a Fresh Stromal Microenvironment In Vivo J. Virol., October 15, 2004; 78(20): 11385 - 11392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. de Repentigny, D. Lewandowski, and P. Jolicoeur Immunopathogenesis of Oropharyngeal Candidiasis in Human Immunodeficiency Virus Infection Clin. Microbiol. Rev., October 1, 2004; 17(4): 729 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. O. TER KUILE, M. E. PARISE, F. H. VERHOEFF, V. UDHAYAKUMAR, R. D. NEWMAN, A. M. VAN EIJK, S. J. ROGERSON, and R. W. STEKETEE THE BURDEN OF CO-INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 AND MALARIA IN PREGNANT WOMEN IN SUB-SAHARAN AFRICA Am J Trop Med Hyg, August 1, 2004; 71(2_suppl): 41 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Kay, P. Yue, Z. Hanna, S. Jothy, E. Tremblay, and P. Jolicoeur Cardiac Disease in Transgenic Mice Expressing Human Immunodeficiency Virus-1 Nef in Cells of the Immune System Am. J. Pathol., July 1, 2002; 161(1): 321 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Forman, R. M. Welsh, T. G. Markees, B. A. Woda, J. P. Mordes, A. A. Rossini, and D. L. Greiner Viral Abrogation of Stem Cell Transplantation Tolerance Causes Graft Rejection and Host Death by Different Mechanisms J. Immunol., June 15, 2002; 168(12): 6047 - 6056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Azzoni, E. Papasavvas, J. Chehimi, J. R. Kostman, K. Mounzer, J. Ondercin, B. Perussia, and L. J. Montaner Sustained Impairment of IFN-{gamma} Secretion in Suppressed HIV-Infected Patients Despite Mature NK Cell Recovery: Evidence for a Defective Reconstitution of Innate Immunity J. Immunol., June 1, 2002; 168(11): 5764 - 5770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Holznagel, S. Norley, S. Holzammer, C. Coulibaly, and R. Kurth Immunological changes in simian immunodeficiency virus (SIVagm)-infected African green monkeys (AGM): expanded cytotoxic T lymphocyte, natural killer and B cell subsets in the natural host of SIVagm J. Gen. Virol., March 1, 2002; 83(3): 631 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Thiebot, F. Louache, B. Vaslin, T. de Revel, O. Neildez, J. Larghero, W. Vainchenker, D. Dormont, and R. Le Grand Early and Persistent Bone Marrow Hematopoiesis Defect in Simian/Human Immunodeficiency Virus-Infected Macaques despite Efficient Reduction of Viremia by Highly Active Antiretroviral Therapy during Primary Infection J. Virol., December 1, 2001; 75(23): 11594 - 11602. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. J White Mitochondrial toxicity and HIV therapy Sex Transm Inf, June 1, 2001; 77(3): 158 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Majka, A. Janowska-Wieczorek, J. Ratajczak, K. Ehrenman, Z. Pietrzkowski, M. A. Kowalska, A. M. Gewirtz, S. G. Emerson, and M. Z. Ratajczak Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner Blood, May 15, 2001; 97(10): 3075 - 3085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Levine, D. T. Scadden, J. A. Zaia, and A. Krishnan Hematologic Aspects of HIV/AIDS Hematology, January 1, 2001; 2001(1): 463 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Koka, B. D. Jamieson, D. G. Brooks, and J. A. Zack Human Immunodeficiency Virus Type 1-Induced Hematopoietic Inhibition Is Independent of Productive Infection of Progenitor Cells In Vivo J. Virol., November 1, 1999; 73(11): 9089 - 9097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ishii, M. Nishihara, F. Ma, Y. Ebihara, K. Tsuji, S. Asano, T. Nakahata, and T. Maekawa Expression of Stromal Cell-Derived Factor-1/Pre-B Cell Growth-Stimulating Factor Receptor, CXC Chemokine Receptor 4, on CD34+ Human Bone Marrow Cells Is a Phenotypic Alteration for Committed Lymphoid Progenitors J. Immunol., October 1, 1999; 163(7): 3612 - 3620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aiuti, L. Turchetto, M. Cota, A. Cipponi, A. Brambilla, C. Arcelloni, R. Paroni, E. Vicenzi, C. Bordignon, and G. Poli Human CD34+ Cells Express CXCR4 and Its Ligand Stromal Cell-Derived Factor-1. Implications for Infection by T-Cell Tropic Human Immunodeficiency Virus Blood, July 1, 1999; 94(1): 62 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lee, J. Ratajczak, R. W. Doms, A. M. Gewirtz, and M. Z. Ratajczak Coreceptor/Chemokine Receptor Expression on Human Hematopoietic Cells: Biological Implications for Human Immunodeficiency Virus-Type 1 Infection Blood, February 15, 1999; 93(4): 1145 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Berkowitz, K. P. Beckerman, T. J. Schall, and J. M. McCune CXCR4 and CCR5 Expression Delineates Targets for HIV-1 Disruption of T Cell Differentiation J. Immunol., October 1, 1998; 161(7): 3702 - 3710. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1998 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Introduction
References
cells from peripheral blood of healthy
volunteers, cultured the cells at densities of 104/mL in
the presence of saturating quantities of Steel factor, erythropoietin
(Epo), GM-CSF, and IL-3, pelleted the cells, and resuspended them in 50 mL in the presence of HIV-1, HIVIIIB, or NL4-3 strains for 2 hours. The
cells were then diluted to 200 mL, cultured overnight, and were then
washed and plated in methylcellulose medium at a density of one cell
per plate. Colonies were plucked for p24 analysis (enzyme-linked
immunosorbent assay [ELISA]) and for HIV-1 tat mRNA reverse
transcriptase-polymerase chain reaction (RT-PCR). Twelve percent of
CFU-GM colonies were p24 antigen+ and 23% were positive
for tat mRNA. Seventeen percent of BFU-E colonies were tat
mRNA+ but only 1 of 37 clones was positive for p24. No
CFU-GEMM progeny were positive for virus. Appropriate control vectors,
including heat-inactivated virus, were used. Consequently, under these
clearly defined ex vivo conditions, progenitor cells are infectable,
but, more importantly for further consideration of the question of marrow failure, HIV-1 infection ex vivo does not impair the capacity of
either CFU-GM or BFU-E to undergo clonal replication or differentiation because differentiated colonial progeny contain the provirus.
(PKC
(TNF-
(IFN-
, IL-6, and IL-8 was stimulated, expression of M, G-,
and GM-CSF was inhibited.
+, and d-TCS-1+ T cells. No such effect
was seen in cultures of normal marrow samples. Further experiments
showed that direct cellular contact between effector and hematopoietic
progenitor cells was essential and that IFN-
, release IL-10 in an
autocrine fashion. MVEC infected with HIV-1 express CD40 and bind to
lymphoma cell CD40L, a process that activates VCAM-1 expression and
subsequent binding with its cognate ligand VLA-4.
Introduction
Implications for AIDS dementia.
Adv Neuroimmunol
4:239,
1994